Picture EBD Group Biotech Showcase 2024 San Francisco 650x100px
Document › Details

Novacyt S.A.. (10/18/17). "Press Release: Proposed Admission to Trading on AIM and Successful Capital Riase of €9.7 Million [Not for US, AU, CA, JP or ZA or any other jurisdiction where unlawful]". Paris & Cambridge.

Region Region London, Greater London
  Country United Kingdom (GB)
Organisations Organisation Novacyt S.A. (Euronext Growh: ALNOV, AIM: NCYT)
  Group Novacyt (Group)
  Organisation 2 Stifel Nicolaus Europe Ltd.
  Group Stifel (Group)
Products Product investment banking
Index term Index term Novacyt–SEVERAL: investment, 201710 capital increase €9.7m with 14.74m new shares at €0.66/share
Persons Person Mullis, Graham (Novacyt 201409 CEO before Lab21 CEO)
  Person 2 Dyer, Anthony (Novacyt 201409– Finance Director before part time Group Financial Controller)

Record changed: 2023-06-05


Picture Twist Bioscience Biopharma Solutions Our Gold Standard 650x200px

More documents for Novacyt (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Kenes Exhibitions Biomed Israel 2024 Tel Aviv 650x300px

» top